Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Prothix, Bioceros, Antitope and University Medical Center Utrecht awarded Eurostars grant

Utrecht, The Netherlands, May 22nd, 2012 - Dutch Biotech companies Prothix BV and Bioceros BV, University Medical Center Utrecht (UMCU, the Netherlands) and UK biotech company Antitope Ltd. announce that they have been awarded a grant within Eureka’s Eurostars™ program with a total budget of over €1.6 million for the pre-clinical development of a monoclonal antibody as a novel anticoagulant with a favorable benefit to risk ratio.
René Verdonk, CEO Prothix, commented: “This is a major step forward for our development program. All consortium members have specific complementary know-how and expertise that ensure an efficient development trajectory. I am looking forward to a fruitful collaboration.”
Erik Hack, professor of Immunology, UMCU, said: “This project highlights the valorization efforts of UMCU. It will be exciting to cooperate with commercial partners, and to see such a cooperation resulting in a new therapeutic product that will help specific patient groups.”
Bram Bout, CEO of Bioceros, said: 'This collaboration fits well in Bioceros’ strategy to use its technology platform to co-develop promising early stage monoclonal antibody products. We are excited about working with this expert team on leveraging this anticoagulant product”.
Neil Butt, BD Director of Antitope, said: “We are delighted to apply Antitope’s Composite Human Antibody technology towards the development of this novel anticoagulant product. We think that the consortium as a whole offers exceptional complementary expertise in developing a therapeutic where there is a real clinical need.”
About Eurostars™
Eurostars is a European research and development project that can address any technological area, but must have a civilian purpose and be aimed at the development of a new product, process or service. The Eurostars project is collaborative, meaning it must involve at least two participants from two different Eurostars member countries.

The Eurostars project should be market-driven: it must have a maximum duration of three years, and within two years of project completion, the product of the research should be ready for launch onto the market. The exception to this rule applies to biomedical or medical projects, where clinical trials must be started within two years of project completion.

About Prothix
Prothix is a Dutch biopharmaceutical company focused on the development of protein therapeutics in the field of coagulation and inflammation. Product leads, discovered by the company or licensed in from academia, are selected based on medical need, potential markets and customer needs and meet a so-called niche-buster profile, i.e. they will be developed for niche indications to obtain clinical proof of concept, while having blockbuster promise for other indications. Prothix adds value to these leads by executing preclinical proof of concept and early development studies.
For further information, please visit or contact:
Prothix BV
René Verdonk, CEO
Tel: +31 (0) 6 202 77 623

About Bioceros
Bioceros is a biotech company offering services on early pre-clinical development of recombinant proteins, with an emphasis on monoclonal antibodies. Services include the generation of monoclonal antibodies in mice, generating high protein producing CHO and PER.C6® cell lines, process development and pre-clinical manufacturing at 20L scale and assay development. This is all Quality Controlled, using state of the art serum-free culture media, such that the generated cell lines can be used for GMP manufacturing. Bioceros is allowed to use Potelligent® technology of BioWa / Kyowa Hakko Kirin for licensees and is preferred vendor of PER.C6® cell development services for DSM Biologics and Crucell.
For further information, please visit or contact:
Bioceros BV
Remco Brandt, COO
Tel: +31 (0) 30 253 7910

About Antitope
Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology enables preclinical analysis of the potential for immunogenicity of therapeutic antibodies and proteins. Antitope's proprietary Composite Human Antibody™ technology results in the generation of humanised antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.
For more information, please visit contact:

Antitope Ltd.
Dr Neil Butt, Business Development Director
Tel: +44 (0)1223 496190

About The University Medical Center of Utrecht (UMC Utrecht)
UMC Utrecht is one of the largest public healthcare institutions in the Netherlands. With almost 11,000 employees, UMC Utrecht is constantly building on the provision of good healthcare services, based on the right people and knowledge. UMC Utrecht aims to be an internationally leading university medical center, where knowledge about health, disease and healthcare is generated, tested, shared and applied. UMC Utrecht is one of the participating centers in the NFU which is the Dutch organization for University Medical Centers. The NFU is the result of a merger of the Netherland’s university hospitals and medical centers.

Publisher Contact Information:

+31 (0) 30 253 7910

Company profile of Bioceros (acquired by Epirus)
Past press releases of Bioceros (acquired by Epirus).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Jun 29€1.3MSecurity
Jun 28€2.2MDatabase
Jun 28€12.0MMaterials
Jun 28€5.5MBusiness applications
Jun 27€3.0MBiopharmaceuticals
Jun 27€10.0MEnergy related
Jun 27N/AWireless applications

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.